Press Releases
March 2, 2026
NEOK Bio Secures FDA IND Clearance for NEOK002, a Novel EGFR/MUC1 Bispecific ADC for Treatment of Solid Tumors
January 21, 2026
NEOK Bio Receives FDA IND Approval for NEOK001, A First-In-Class B7-H3/ROR1 Bispecific ADC for Treatment of Solid Tumor Cancers
November 4, 2025
NEOK Bio Launches from Stealth with $75 Million to Advance Next-Generation Bispecific Antibody Drug Conjugates (ADC) in Oncology
